Santhera Extends Executive Management and Appoints Chief Commercial Officer

Santhera Pharmaceuticals Holding AG / Santhera Extends Executive Management and Appoints Chief Commercial Officer . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, January 30, 2015 - Santhera Pharmaceuticals (SIX: SANN) today announced the strengthening of the leadership team through nomination of senior members of staff to its Executive Management and the appointment of a Chief Commercial Officer.

With effect of February 1, 2015, the Board of Directors announces the expansion of Santhera's leadership team and appointed senior staff members Nicholas Coppard, PhD, SVP Head Development, Günther Metz, PhD, SVP Business Development, and Oliver Strub, General Counsel and Secretary to the Board, to the Executive Management Team headed by CEO Thomas Meier, PhD.

Also effective February 1, 2015, Giovanni Stropoli has been appointed as Chief Commercial Officer for Europe and Rest of World. He will report to the Company's CEO, Thomas Meier, and will also join the Executive Management. Mr. Stropoli joins Santhera from InterMune, recently acquired by Roche, where he was responsible for the successful launch of the breakthrough orphan drug Esbriet^® in 11 countries.

Santhera's commercial organization will be further strengthened by the hiring of professionals with experience in successfully managing the international commercialization of orphan and niche-market drug products. This will extend the Company's competencies in market access, pricing and reimbursement, supply chain and logistics, business planning and operations.

The Company is currently evaluating candidates for the position of CFO who will also become a member of Executive Management.

Martin Gertsch, Chairman of the Board, commented: "The year 2015 could mark a major milestone for Santhera. By evolving our organization, we secure the in-house expertise needed to realize the full potential of the lead product Raxone^®/Catena^® and to build and advance the Company's pipeline. We are absolutely delighted that we can attract and rely on highly talented professionals, and we believe that the strength of the leadership team will enable us to build sustainable growth and long-term success for Santhera."